Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

What is the purpose of this trial?

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Bayer Healthcare Pharmaceuticals, Inc.

Start Date: 03/04/2016

End Date: 01/31/2019

Last Updated: 02/22/2018

Study HIC#: 1511016772

Get Involved

For more information about this study, contact:
Lauren Liberti
+1 203-737-8010
lauren.liberti@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Aldo Peixoto

Principal Investigator

Sub-Investigators